(Q34974196)

5 August 2017

title

Impact of new drugs and biologics on colorectal cancer treatment and costs. (English)

1 reference

5 August 2017

1 reference

1 reference

Pinar Karaca-Mandic

1

1 reference

5 August 2017

Jeffrey S McCullough

2

1 reference

5 August 2017

Mustaqeem A Siddiqui

3

1 reference

5 August 2017

Holly Van Houten

4

1 reference

5 August 2017

Nilay D Shah

5

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

Journal of Oncology Practice

5 August 2017

published in

1 reference

5 August 2017

volume

7

1 reference

5 August 2017

issue

3 Suppl

1 reference

5 August 2017

page(s)

e30s-7s

1 reference

Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Impact of specialty drugs on the use of other medical services.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Evaluation of trends in the cost of initial cancer treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Second-line and third-line chemotherapy for lung cancer: use and cost.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

The effect of using newer drugs on admissions of elderly Americans to hospitals and nursing homes: state-level evidence from 1997 to 2003.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Cost of cancer care: issues and implications

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

The price tag on progress--chemotherapy for colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

The use of drugs in combination for the treatment of cancer: rationale and results

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Fluorouracil and leucovorin for metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Do newer prescription drugs pay for themselves? A reassessment of the evidence

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3092464

New cardiovascular drugs: patterns of use and association with non-drug health expenditures

9 December 2018

1 reference

12 December 2020

SPIKE$: a six-step protocol for delivering bad news about the cost of medical care

1 reference

12 December 2020

The value of new chemotherapeutic agents for metastatic colorectal cancer

1 reference

12 December 2020

Systemic treatment of colorectal cancer

1 reference

12 December 2020

The economic burden of lung cancer and the associated costs of treatment failure in the United States

1 reference

12 December 2020

Identifiers

DOI

10.1200/JOP.2011.000302

1 reference

5 August 2017

1 reference

5 August 2017

1 reference